N-Acetyl Semax amidate
Not FDA approvedSynthetic ACTH-derived neuropeptide
Also known as: NA-Semax, NA Semax amidate, N-acetyl semax
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Anecdotal. Community reports, no controlled data
- No registered human trials. Nothing registered on ClinicalTrials.gov
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
N-Acetyl Semax amidate is a chemically modified version of Semax, a synthetic peptide based on a fragment of adrenocorticotropic hormone (ACTH 4-10). The added acetyl and amide groups are intended to make the molecule more stable and longer lasting than Semax itself. It is thought to act on brain signaling pathways similar to Semax, such as influencing neurotrophic factors like BDNF, but this has not been shown for the modified form.
What the evidence shows
There are no registered human trials and no published papers found on this specific modified form, so claims about its effects rest on community reports and extrapolation from research on the parent compound Semax. It is not FDA-approved, and its effects and safety in humans are unknown.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Sources
- PubChem compound record (CID 172638603)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.